James S. Nowick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
James S. Nowick has a total of 247 co-authors. Here are the top co-authors by number of shared publications:
- Adam G. Kreutzer
Department of Chemistry, University of California, Irvine, Irvine, California 92697, United States
34 shared publications - Gretchen Guaglianone
Department of Chemistry, University of California, Irvine, Irvine, California 92697, United States
13 shared publications - Ryan K. Spencer
Department of Chemistry, University of California, Irvine , Irvine, California 92697-2025, United States
12 shared publications - Michael A. Morris
Department of Chemistry, University of California, Irvine, CA, 92697-2025, United States
10 shared publications - Stan Yoo
Department of Chemistry, University of California, Irvine , Irvine, California 92697-2025, United States
10 shared publications Adam G. Kreutzer
Department of Chemistry, University of California, Irvine, Irvine, California 92697-2025, USA
9 shared publications
Latest Publications
- 27 September 2025
- Published by Elsevier
- Vol. 723, 477-509
Using solution-phase NMR spectroscopy to study the folding and supramolecular assembly of conformationally constrained β-sheet peptides
- 27 September 2025
- Published by Elsevier
- Vol. 723, 477-509
Using solution-phase NMR spectroscopy to study the folding and supramolecular assembly of conformationally constrained β-sheet peptides
- 22 September 2025
- Published by Elsevier
- Vol. 723, 21-45
Cyclic β-sheet peptides
- Open Access
- 8 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0331024
Antibodies raised against a structurally defined Aβ oligomer mimic protect human iPSC neurons from Aβ toxicity at sub-stoichiometric concentrations
Anti-Aβ antibodies are important tools for identifying structural features of aggregates of the Aβ peptide and are used in many aspects of Alzheimer’s disease (AD) research. Our laboratory recently reported the generation of a polyclonal antibody, pAb2AT-L, that is moderately selective for oligomeric Aβ over monomeric and fibrillar Aβ and recognizes the diffuse peripheries of Aβ plaques in AD brain tissue but does not recognize the dense fibrillar plaque cores. This antibody was generated against 2AT-L, a structurally defined Aβ oligomer mimic composed of three Aβ-derived β-hairpins arranged in a triangular fashion and covalently stabilized with three disulfide bonds. In the current study, we set out to determine if pAb2AT-L is neuroprotective against toxic aggregates of Aβ and found that pAb2AT-L protects human iPSC-derived neurons from Aβ42-mediated toxicity at molar ratios as low as 1:100 antibody to Aβ42, with a ratio of 1:25 almost completely rescuing cell viability. Few other antibodies have been reported to exhibit neuroprotective effects at such low ratios of antibody to Aβ. ThT and TEM studies indicate that pAb2AT-L delays but does not completely inhibit Aβ42 fibrillization at sub-stoichiometric ratios. The ability of pAb2AT-L to inhibit Aβ42 toxicity and aggregation at sub-stoichiometric ratios suggests that pAb2AT-L binds toxic Aβ42 oligomers and does not simply sequester monomeric Aβ42. These results further suggest that toxic oligomers of Aβ42 share significant structural similarities with 2AT-L.
- 8 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0331024
Open AccessAntibodies raised against a structurally defined Aβ oligomer mimic protect human iPSC neurons from Aβ toxicity at sub-stoichiometric concentrations
Anti-Aβ antibodies are important tools for identifying structural features of aggregates of the Aβ peptide and are used in many aspects of Alzheimer’s disease (AD) research. Our laboratory recently reported the generation of a polyclonal antibody, pAb2AT-L, that is moderately selective for oligomeric Aβ over monomeric and fibrillar Aβ and recognizes the diffuse peripheries of Aβ plaques in AD brain tissue but does not recognize the dense fibrillar plaque cores. This antibody was generated against 2AT-L, a structurally defined Aβ oligomer mimic composed of three Aβ-derived β-hairpins arranged in a triangular fashion and covalently stabilized with three disulfide bonds. In the current study, we set out to determine if pAb2AT-L is neuroprotective against toxic aggregates of Aβ and found that pAb2AT-L protects human iPSC-derived neurons from Aβ42-mediated toxicity at molar ratios as low as 1:100 antibody to Aβ42, with a ratio of 1:25 almost completely rescuing cell viability. Few other antibodies have been reported to exhibit neuroprotective effects at such low ratios of antibody to Aβ. ThT and TEM studies indicate that pAb2AT-L delays but does not completely inhibit Aβ42 fibrillization at sub-stoichiometric ratios. The ability of pAb2AT-L to inhibit Aβ42 toxicity and aggregation at sub-stoichiometric ratios suggests that pAb2AT-L binds toxic Aβ42 oligomers and does not simply sequester monomeric Aβ42. These results further suggest that toxic oligomers of Aβ42 share significant structural similarities with 2AT-L.
- Open Access
- 28 August 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Using solution-phase NMR spectroscopy to study the folding and supramolecular assembly of conformationally constrained β-sheet peptides
Conformationally constrained β-sheet peptides are a valuable model system for studying the folding and supramolecular assembly of aggregation-prone peptides. Understanding how these peptides assemble into soluble oligomers is central to understanding the molecular assembly of amyloid diseases. This chapter describes how to study the folding and supramolecular assembly of β-sheet peptides by solution-phase NMR spectroscopy. First, the chapter describes how to prepare an NMR sample and acquire NMR data. Then, the chapter describes how to assign residues and identify spectroscopic hallmarks of -sheet folding. Next, the chapter describes how to use isotopic labeling to verify key intermolecular contact. The chapter concludes with the spectroscopic hallmarks of supramolecular assembly. This chapter focuses on the -sheet peptides but can be generalized to the studying the folding and supramolecular assembly of a wide variety of peptides.
- 28 August 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessUsing solution-phase NMR spectroscopy to study the folding and supramolecular assembly of conformationally constrained β-sheet peptides
Conformationally constrained β-sheet peptides are a valuable model system for studying the folding and supramolecular assembly of aggregation-prone peptides. Understanding how these peptides assemble into soluble oligomers is central to understanding the molecular assembly of amyloid diseases. This chapter describes how to study the folding and supramolecular assembly of β-sheet peptides by solution-phase NMR spectroscopy. First, the chapter describes how to prepare an NMR sample and acquire NMR data. Then, the chapter describes how to assign residues and identify spectroscopic hallmarks of -sheet folding. Next, the chapter describes how to use isotopic labeling to verify key intermolecular contact. The chapter concludes with the spectroscopic hallmarks of supramolecular assembly. This chapter focuses on the -sheet peptides but can be generalized to the studying the folding and supramolecular assembly of a wide variety of peptides.
- Open Access
Antibodies raised against a structurally defined Aβ oligomer mimic protect human iPSC neurons from Aβ toxicity at sub-stoichiometric concentrations
Anti-Aβ antibodies are important tools for identifying structural features of aggregates of the Aβ peptide and are used in many aspects of Alzheimer’s disease (AD) research. Our laboratory recently reported the generation of a polyclonal antibody, pAb 2AT-L , that is moderately selective for oligomeric Aβ over monomeric and fibrillar Aβ and recognizes the diffuse peripheries of Aβ plaques in AD brain tissue but does not recognize the dense fibrillar plaque cores. This antibody was generated against 2AT-L, a structurally defined Aβ oligomer mimic composed of three Aβ-derived β-hairpins arranged in a triangular fashion and covalently stabilized with three disulfide bonds. In the current study, we set out to determine if pAb 2AT-L is neuroprotective against toxic aggregates of Aβ and found that pAb 2AT-L protects human iPSC-derived neurons from Aβ 42 -mediated toxicity at molar ratios as low as 1:100 antibody to Aβ 42 , with a ratio of 1:25 almost completely rescuing cell viability. Few other antibodies have been reported to exhibit neuroprotective effects at such low ratios of antibody to Aβ. ThT and TEM studies indicate that pAb 2AT-L delays but does not completely inhibit Aβ 42 fibrillization at sub-stoichiometric ratios. The ability of pAb 2AT-L to inhibit Aβ 42 toxicity and aggregation at sub-stoichiometric ratios suggests that pAb 2AT-L binds toxic Aβ 42 oligomers and does not simply sequester monomeric Aβ 42 . These results further suggest that toxic oligomers of Aβ 42 share significant structural similarities with 2AT-L. TOC Graphic:
Open AccessAntibodies raised against a structurally defined Aβ oligomer mimic protect human iPSC neurons from Aβ toxicity at sub-stoichiometric concentrations
Anti-Aβ antibodies are important tools for identifying structural features of aggregates of the Aβ peptide and are used in many aspects of Alzheimer’s disease (AD) research. Our laboratory recently reported the generation of a polyclonal antibody, pAb 2AT-L , that is moderately selective for oligomeric Aβ over monomeric and fibrillar Aβ and recognizes the diffuse peripheries of Aβ plaques in AD brain tissue but does not recognize the dense fibrillar plaque cores. This antibody was generated against 2AT-L, a structurally defined Aβ oligomer mimic composed of three Aβ-derived β-hairpins arranged in a triangular fashion and covalently stabilized with three disulfide bonds. In the current study, we set out to determine if pAb 2AT-L is neuroprotective against toxic aggregates of Aβ and found that pAb 2AT-L protects human iPSC-derived neurons from Aβ 42 -mediated toxicity at molar ratios as low as 1:100 antibody to Aβ 42 , with a ratio of 1:25 almost completely rescuing cell viability. Few other antibodies have been reported to exhibit neuroprotective effects at such low ratios of antibody to Aβ. ThT and TEM studies indicate that pAb 2AT-L delays but does not completely inhibit Aβ 42 fibrillization at sub-stoichiometric ratios. The ability of pAb 2AT-L to inhibit Aβ 42 toxicity and aggregation at sub-stoichiometric ratios suggests that pAb 2AT-L binds toxic Aβ 42 oligomers and does not simply sequester monomeric Aβ 42 . These results further suggest that toxic oligomers of Aβ 42 share significant structural similarities with 2AT-L. TOC Graphic:
- 27 February 2025
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 23 (16) , 3881-3893
A β-hairpin peptide derived from Aβ forms different oligomers in the crystal state and in aqueous solution
The supramolecular assembly of amyloid-β into soluble oligomers is critical Alzheimer's disease (AD) progression. Soluble Aβ oligomers have emerged as neurotoxic species involved in AD progression and some Aβ oligomers are thought to be composed of β-hairpins. In this work, we report the X-ray crystallographic and solution-phase assembly of a macrocyclic β-hairpin peptide that mimics a β-hairpin formed by Aβ16–36. In the crystal lattice, the peptide assembles into a symmetric hexamer composed of two identical triangular trimers. In aqueous solution, the peptide assembles to form an asymmetric hexamer. 1H NMR, TOCSY, and 1H,15N HSQC experiments establish that the asymmetric hexamer contains two different species, A and B. 15N-edited NOESY reveals that species A is a cylindrin-like trimer and species B is a triangular trimer that collectively constitute the asymmetric hexamer. Diffusion-ordered NMR spectroscopy (DOSY) suggests that two asymmetric hexamers further assemble to form a dodecamer. NMR-guided molecular mechanics and molecular dynamics studies provide a model for the asymmetric hexamer and suggest how two asymmetric hexamers can form a dodecamer. Solution-phase NMR studies of analogues show that intermolecular hydrogen bonding and the formation of a hydrophobic core help stabilize the asymmetric hexamer. These NMR and crystallographic studies illustrate how an Aβ β-hairpin peptide can assemble to form different well-defined oligomers in the crystal state and in aqueous solution, providing a deeper understanding of the heterogeneity of Aβ oligomers and new structural models of Aβ oligomers composed of Aβ β-hairpins.
- 27 February 2025
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 23 (16) , 3881-3893
A β-hairpin peptide derived from Aβ forms different oligomers in the crystal state and in aqueous solution
The supramolecular assembly of amyloid-β into soluble oligomers is critical Alzheimer's disease (AD) progression. Soluble Aβ oligomers have emerged as neurotoxic species involved in AD progression and some Aβ oligomers are thought to be composed of β-hairpins. In this work, we report the X-ray crystallographic and solution-phase assembly of a macrocyclic β-hairpin peptide that mimics a β-hairpin formed by Aβ16–36. In the crystal lattice, the peptide assembles into a symmetric hexamer composed of two identical triangular trimers. In aqueous solution, the peptide assembles to form an asymmetric hexamer. 1H NMR, TOCSY, and 1H,15N HSQC experiments establish that the asymmetric hexamer contains two different species, A and B. 15N-edited NOESY reveals that species A is a cylindrin-like trimer and species B is a triangular trimer that collectively constitute the asymmetric hexamer. Diffusion-ordered NMR spectroscopy (DOSY) suggests that two asymmetric hexamers further assemble to form a dodecamer. NMR-guided molecular mechanics and molecular dynamics studies provide a model for the asymmetric hexamer and suggest how two asymmetric hexamers can form a dodecamer. Solution-phase NMR studies of analogues show that intermolecular hydrogen bonding and the formation of a hydrophobic core help stabilize the asymmetric hexamer. These NMR and crystallographic studies illustrate how an Aβ β-hairpin peptide can assemble to form different well-defined oligomers in the crystal state and in aqueous solution, providing a deeper understanding of the heterogeneity of Aβ oligomers and new structural models of Aβ oligomers composed of Aβ β-hairpins.
- Open Access
- 14 February 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (8) , 6343-6348
Vancomycin–Teixobactin Conjugates
Vancomycin continues to be a widely used antibiotic of last resort in treating drug-resistant pathogens despite the emergence of vancomycin-resistant strains such as vancomycin-resistant Enterococci (VRE). This communication reports that conjugation of vancomycin to a second antibiotic that targets a different region of lipid II enhances and rescues its antibiotic activity. Conjugation of vancomycin to a minimal teixobactin pharmacophore in which residues 1-6 are replaced with an aromatic amide results in substantial enhancement in activity over the individual components or mixtures thereof. Three conjugates with minimum inhibitory concentrations (MICs) of 0.5 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA) and 0.063-0.125 μg/mL against methicillin-susceptible Staphylococcus aureus (MSSA) were identified. Each of these conjugates is also active against VRE, even though the individual components are inactive, with the most active conjugate (Cbp-Lys10-teixo7-11-vanco) having an MIC of 2-4 μg/mL. These findings demonstrate that conjugation of vancomycin to a minimal teixobactin pharmacophore is an effective strategy for enhancing the activity of vancomycin against important Gram-positive pathogens.
- 14 February 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (8) , 6343-6348
Open AccessVancomycin–Teixobactin Conjugates
Vancomycin continues to be a widely used antibiotic of last resort in treating drug-resistant pathogens despite the emergence of vancomycin-resistant strains such as vancomycin-resistant Enterococci (VRE). This communication reports that conjugation of vancomycin to a second antibiotic that targets a different region of lipid II enhances and rescues its antibiotic activity. Conjugation of vancomycin to a minimal teixobactin pharmacophore in which residues 1-6 are replaced with an aromatic amide results in substantial enhancement in activity over the individual components or mixtures thereof. Three conjugates with minimum inhibitory concentrations (MICs) of 0.5 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA) and 0.063-0.125 μg/mL against methicillin-susceptible Staphylococcus aureus (MSSA) were identified. Each of these conjugates is also active against VRE, even though the individual components are inactive, with the most active conjugate (Cbp-Lys10-teixo7-11-vanco) having an MIC of 2-4 μg/mL. These findings demonstrate that conjugation of vancomycin to a minimal teixobactin pharmacophore is an effective strategy for enhancing the activity of vancomycin against important Gram-positive pathogens.
- Open Access
- 27 January 2025
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 90 (5) , 2132-2136
Potent Analogues of Clovibactin from Commercially Available Amino Acid Building Blocks
This paper reports highly active analogues of clovibactin in which the rare, noncanonical amino acid d-hydroxyasparagine is replaced with the commercially available amino acid d-threonine. Sequential mutation of leucines 2, 7, and 8 to the more hydrophobic homologue cyclohexylalanine dramatically increases the antibiotic activity of d-Thr5-clovibactin. The resulting analogues (d-Cha2,d-Thr5-clovibactin, Cha7,d-Thr5-clovibactin, and Cha8,d-Thr5-clovibactin) are readily prepared by standard peptide synthesis techniques and exhibit excellent activity (≤1 μg/mL) against the Gram-positive, drug-resistant pathogens MRSA and VRE.
- 27 January 2025
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 90 (5) , 2132-2136
Open AccessPotent Analogues of Clovibactin from Commercially Available Amino Acid Building Blocks
This paper reports highly active analogues of clovibactin in which the rare, noncanonical amino acid d-hydroxyasparagine is replaced with the commercially available amino acid d-threonine. Sequential mutation of leucines 2, 7, and 8 to the more hydrophobic homologue cyclohexylalanine dramatically increases the antibiotic activity of d-Thr5-clovibactin. The resulting analogues (d-Cha2,d-Thr5-clovibactin, Cha7,d-Thr5-clovibactin, and Cha8,d-Thr5-clovibactin) are readily prepared by standard peptide synthesis techniques and exhibit excellent activity (≤1 μg/mL) against the Gram-positive, drug-resistant pathogens MRSA and VRE.
- Open Access
- 27 December 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Potent Analogues of Clovibactin from Commercially Available Amino Acid Building Blocks
This paper reports highly active analogues of clovibactin in which the rare, non-canonical amino acid D-hydroxyasparagine is replaced with the commercially available amino acid D-threonine. Sequential mutation of leucines 2, 7, and 8 to the more hydrophobic homologue cyclohexylalanine dramatically increases the antibiotic activity of D-Thr5-clovibactin. The resulting analogues (D-Cha2,D-Thr5-clovibactin, Cha7,D-Thr5-clovibactin, and Cha8,D-Thr5-clovibactin) are readily prepared by standard peptide synthesis techniques and exhibit excellent activity (≤ 1 μg/mL) against the Gram-positive, drug-resistant pathogens MRSA and VRE.
- 27 December 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessPotent Analogues of Clovibactin from Commercially Available Amino Acid Building Blocks
This paper reports highly active analogues of clovibactin in which the rare, non-canonical amino acid D-hydroxyasparagine is replaced with the commercially available amino acid D-threonine. Sequential mutation of leucines 2, 7, and 8 to the more hydrophobic homologue cyclohexylalanine dramatically increases the antibiotic activity of D-Thr5-clovibactin. The resulting analogues (D-Cha2,D-Thr5-clovibactin, Cha7,D-Thr5-clovibactin, and Cha8,D-Thr5-clovibactin) are readily prepared by standard peptide synthesis techniques and exhibit excellent activity (≤ 1 μg/mL) against the Gram-positive, drug-resistant pathogens MRSA and VRE.
- Open Access
- 17 December 2024
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 90 (1) , 394-400
α-Methylation Enables the X-ray Crystallographic Observation of Oligomeric Assemblies Formed by a β-Hairpin Peptide Derived from Aβ
The assembly of the β-amyloid peptide Aβ into toxic oligomers plays a significant role in the neurodegeneration associated with the pathogenesis of Alzheimer's disease. Our laboratory has developed N-methylation as a tool to enable X-ray crystallographic studies of oligomers formed by macrocyclic β-hairpin peptides derived from Aβ. In this investigation, we set out to determine whether α-methylation could be used as an alternative to N-methylation in studying the oligomerization of a β-hairpin peptide derived from Aβ. α-Methylation permits the crystallographic assembly of a triangular trimer and ball-shaped dodecamer, resembling assemblies formed by the N-methylated homolog. Subtle differences are observed in the conformation of the α-methylated peptide when compared to the N-methylated homolog. Notably, α-methylation appears to promote a flatter and more extended β-sheet conformation than that of N-methylated β-sheets or a typical unmodified β-sheet. α-Methylation provides an alternative to N-methylation in X-ray crystallographic studies of oligomers formed by peptides derived from Aβ, with the attractive feature of preserving NH hydrogen-bond donors along the peptide backbone.
- 17 December 2024
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 90 (1) , 394-400
Open Accessα-Methylation Enables the X-ray Crystallographic Observation of Oligomeric Assemblies Formed by a β-Hairpin Peptide Derived from Aβ
The assembly of the β-amyloid peptide Aβ into toxic oligomers plays a significant role in the neurodegeneration associated with the pathogenesis of Alzheimer's disease. Our laboratory has developed N-methylation as a tool to enable X-ray crystallographic studies of oligomers formed by macrocyclic β-hairpin peptides derived from Aβ. In this investigation, we set out to determine whether α-methylation could be used as an alternative to N-methylation in studying the oligomerization of a β-hairpin peptide derived from Aβ. α-Methylation permits the crystallographic assembly of a triangular trimer and ball-shaped dodecamer, resembling assemblies formed by the N-methylated homolog. Subtle differences are observed in the conformation of the α-methylated peptide when compared to the N-methylated homolog. Notably, α-methylation appears to promote a flatter and more extended β-sheet conformation than that of N-methylated β-sheets or a typical unmodified β-sheet. α-Methylation provides an alternative to N-methylation in X-ray crystallographic studies of oligomers formed by peptides derived from Aβ, with the attractive feature of preserving NH hydrogen-bond donors along the peptide backbone.